Insider Selling: Twist Bioscience (NASDAQ:TWST) CFO Sells $189,116.25 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 5,875 shares of the company’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $189,116.25. Following the completion of the transaction, the chief financial officer directly owned 97,042 shares in the company, valued at $3,123,781.98. This represents a 5.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Adam Laponis also recently made the following trade(s):

• On Thursday, October 9th, Adam Laponis sold 2,517 shares of Twist Bioscience stock. The shares were sold at an average price of $32.92, for a total value of $82,859.64.
• On Wednesday, October 8th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The shares were sold at an average price of $31.15, for a total value of $93,450.00.

Twist Bioscience Trading Down 2.2%

Shares of TWST opened at $31.19 on Friday. The business’s 50-day moving average price is $27.63 and its 200 day moving average price is $32.66. The stock has a market capitalization of $1.88 billion, a P/E ratio of -21.51 and a beta of 2.38. Twist Bioscience Corporation has a 1-year low of $24.07 and a 1-year high of $55.33. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. The firm had revenue of $96.06 million for the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC raised its holdings in Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after buying an additional 303 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after buying an additional 302 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in Twist Bioscience during the second quarter valued at about $97,000. Bayforest Capital Ltd raised its holdings in Twist Bioscience by 49.3% during the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock valued at $191,000 after buying an additional 1,604 shares in the last quarter. Finally, Pallas Capital Advisors LLC acquired a new position in Twist Bioscience during the first quarter valued at approximately $201,000.

Analyst Ratings Changes

A number of equities analysts recently commented on TWST shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Evercore ISI reduced their price objective on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Barclays reduced their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, October 2nd. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.